|1.||Shames, David M: 2 articles (05/2009 - 09/2005)|
|2.||Brasch, Robert C: 2 articles (05/2009 - 09/2005)|
|3.||Fu, Yanjun: 2 articles (05/2009 - 09/2005)|
|4.||Raatschen, Hans-Juergen: 1 article (05/2009)|
|5.||Pietsch, Hubertus: 1 article (05/2009)|
|6.||Yeh, Benjamin M: 1 article (05/2009)|
|7.||Fournier, Laure S: 1 article (09/2005)|
|8.||Yeh, Benjamin: 1 article (09/2005)|
|9.||Simon, Gerhard H: 1 article (09/2005)|
|10.||Lucidi, Vincenzo: 1 article (09/2005)|
09/01/2005 - "The objective of this study was to evaluate computed tomography (CT) enhancement characteristics for a new iodinated macromolecular contrast medium (MMCM), PEG12000-Gen4-triiodo, for angiographic effect and for assessment of abnormal vascular permeability in cancer. "
05/01/2009 - "Just before and 24 hours after the first injection of anti-VEGF antibody, the tumors were imaged by dynamic CT scans enhanced with PEG12000-Gen4-triiodo (n = 3 rats) or iohexol (n = 3 rats). "
05/01/2009 - "To evaluate the potential of dynamic CT enhanced by iohexol or a novel macromolecular contrast agent, PEG12000-Gen4-triiodo, to monitor microvascular changes in tumors treated with the angiogenesis inhibitor bevacizumab. "
|1.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)